Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

Next Previous
Trial Profile

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Dendritic cell vaccines (Primary) ; Interferon-alpha-2 (Primary) ; Rintatolimod (Primary) ; Ipilimumab; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors
  • Indications Malignant melanoma
  • Focus Therapeutic Use

Most Recent Events

  • 11 May 2025 Planned End Date changed from 13 Nov 2027 to 3 Apr 2026.
  • 11 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 25 Feb 2025 Planned End Date changed from 22 Nov 2025 to 13 Nov 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top